E-Books: A Paradigm Shift and Legal Issues

In the digital era, the publication industry talks more about e-books utility across the world. But in the Indian scenario, usage of e-books is predominantly low compared with other developed countries. The publisher’s strategies like control over e-books platform, licencing and other legal issues are pushing back libraries from the procurement of e-books. This article makes a modest attempt to describe the conceptual framework, advantages, disadvantages, usage, legal issues, access models and licencing pertaining to e-books procurement

Acetylacetonates of Nickel( 11) and Copper( 11) as Accelerators for the Epoxy Resin System

The acetylacetonates of nickel(II) and copper(II) serve as accelerators for the anhydride-curable epoxy resin system. An appreciable lowering in the cure gel time and a substantial increase in the rate of curing is observed with enhanced concentrations of the metal chelates. Cure kinetic studies and cure schedules have been followed using a differential scanning calorimeter. The thermal and electrical insulation characteristics of the cured epoxy system are little affected by the variation of temperature, voltage, and aging under UV radiation. (C) 1994 John Wiley & Sons, Inc

Emerging Trends in Library Marketing and Engagement through Digital Media

Previously, the effectiveness of traditional forms of communication and marketing were adequate in library engagement and marketing activities. In the recent past, the Library Marketing has undergone a lot of change, and the information technology has proved and brought substantial changes in digital marketing channels. With innovative technology, libraries are engaged in a constant search for better ways for communicating its resources and services and marketing them effectively. The internet world has brought all users and libraries together to find each other and share their information requirements. Libraries are capturing its user through multi marketing-channels including social media. Here an attempt has been made to understand the library marketing and engagement tools in the digital era and case study of Alliance University Library as example for marketing e-resources as well

Complexes of ruthenium(II) and ruthenium(III) with tertiary arsines

Ruthenium trichloride reacts with stoichiometric amounts of tertiary arsines in boiling ethanol to give paramagnetic complexes, RuCl3(Ph2RAs)3 (R = Me, Et, Pr, Bu), which react further with 2,2′-bipyridyl(bipy) and o-phenanthroline(phen) to yield brick red crystalline products, RuCl3 (N-N)(Ph2RAs) (N-N = bipy, phen). In the presence of excess arsine Ru(III) is reduced to Ru(II), and trichloro-bridged complexes of the formula [Ru2Cl3(Ph2RAs)6]Cl are formed. These on treatment with carbonylated solutions of rhodium chloride produce yellow crystals of [Ru2Cl3(Ph2RAs)6][RhCl2(CO)2] containing Ru(II) and Rh(I). Several dicarbonyl complexes cis-RuX2(CO)2(Ph2RAs)2 (X = Cl, Br; R = Pr, Bu) have also been isolated. © 1977

Complexes of osmium with tertiary arsines and carbonmonoxide

Osmium halides (Cl and Br) react with monotertiary arsines Ph2RAs (R=Me, Et, Pr and Bu) in alcoholic medium to give paramagnetic octahedral complexes of the type OsX3L3 (X=Cl, Br; L=Ph2RAs) which further react with carbonmonoxide to give dihalo dicarbonyl complexes of osmium(II) of the type OsX2 (CO)2 L2. Similarly, osmium halides react with tertiary arsines in the presence of formaldehyde to give monocarbonyl complexes of osmium(II) of the type OsX2 (CO)L3. Structures have been assigned to all these compounds on the basis of IR and NMR studies. © 1980 Indian Academy of Sciences

arbonyl complexes of rhodium and iridium with tricyclohexyl arsine

Tricyclohexylarsine (L) complexes of Ir and Rh carbonyls were prepd. Thus, treating the carboxylation mixt. from Rh halides with L gave RhXL2(CO) (X = Br, Cl) which added X2 to give RhX3L2(CO)​. Treating the Ir analogs with HX gave IrHX2(CO)​L2, which by dehydrohalogenation gave mixed IrX(CO)​L2 and IrX(CO)​(O)​2L2

Save cells before tooth replantation: A review

Avulsion is one of the most complex traumatic injury affecting both teeth and children. Avulsed teeth can be replanted. Treatment for avulsed teeth should include, pulp and periodontal ligament (PDL) cell management to increase the survival rate of these teeth. If immediate replantation is not possible, the clonicity and progenicity of the viable PDL cells can be maintained with the aid of suitable storage medium at the place of trauma. The incorrect use of a storage medium leads to PDL cell necrosis eventually resulting in ankylosis and replacement resorption of the tooth root. Due to the importance of the storage media in long-term prognosis of the avulsed teeth, an informed choice of a media is essential for a favorable outcome. This review discusses available storage media and their unique features along with pros and cons of each medium

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single‐agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high‐risk features. Here we report the final analysis from RESONATE with median follow‐up on study of 65.3 months (range, 0.3‐71.6) in the ibrutinib arm. Median progression‐free survival (PFS) remained significantly longer for patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113‐0.196; P˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high‐risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080‐0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418‐0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all‐grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long‐term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high‐risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707)